TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.20 | 80.60 | -0.89% |
| CAC 40 | 7,796.31 | 26.36 | -0.34% |
| DAX 40 | 24,264.73 | 24.78 | -0.10% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,989.24 | 2.88 | -0.03% |
| HKSE | 24,994.14 | 168.48 | 0.68% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
| SSE Composite Index | 3,559.79 | 25.31 | 0.72% |